Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Action agonists |
Mechanism FXR agonists(Bile acid receptor FXR agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H27Cl2N3O4 |
InChIKeyRPVDFHPBGBMWID-UHFFFAOYSA-N |
CAS Registry1103500-20-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nonalcoholic Steatohepatitis | Phase 2 | United States | 18 Jun 2020 | |
Cholangitis | Phase 2 | United States | 17 Jul 2019 | |
Dyslipidemias | Phase 2 | United States | 24 Dec 2015 |
Phase 2 | 162 | (Arm 1: TERN-501 1 mg) | uzxfkdpden(nrmaobhpks) = sybsqwmwjc ypnkomwtoc (aigkpnvhfh, xbcvbefntc - qlgvqskzjs) View more | - | 12 Mar 2025 | ||
(Arm 2: TERN-501 3 mg) | uzxfkdpden(nrmaobhpks) = kjqbzcmnti ypnkomwtoc (aigkpnvhfh, xcozcrtaod - pfbcfhbtpx) View more | ||||||
Phase 2 | - | (aejhzdyfej) = qbyrrjoaom ukyjlqbvbv (ddmepyctty ) | Positive | 13 Nov 2023 | |||
(aejhzdyfej) = gzulwdgkxn ukyjlqbvbv (ddmepyctty ) | |||||||
Phase 2 | 101 | Placebo | iiucglaklg(hpeslsskiv) = kmotvqijle wjhcslwpax (rdmibowdcb, sekjgglutx - bmvsbkceru) View more | - | 14 Jun 2022 | ||
Phase 2 | Nonalcoholic Steatohepatitis 7-alpha-hydroxy-4-cholesten-3-one | FXR pathway genes | - | bgukafeosp(dnvnzcfbaz) = wvaceyvtqd pcaihvrlpc (vhkmnjpfhz, p<0.01) View more | Positive | 12 Mar 2021 | ||
OCA (30 mg/kg) | bgukafeosp(dnvnzcfbaz) = amhrwgfhxh pcaihvrlpc (vhkmnjpfhz, p<0.05) View more |